Abstract
The female myocardium, relative to that of the male, exhibits sustained resistance to ischaemic tissue injury, a phenomenon termed sex-specific cardioprotection (SSC). SSC is dependent upon the sarcolemmal KATP channel (sarcKATP), and protein kinase C (PKC). Here we investigate whether PKC-mediated regulation of sarcKATP concentration can explain this endogenous form of protection. Hearts from male (M) and female (F) rats were Langendorff-perfused for 30 min prior to either regional ischaemia-reperfusion (I/R), or global ischaemia (GISC). For both protocols, pre-ischaemic blockade of PKC was achieved by chelerythrine (Chel) in male (M + C) and female (F + C) hearts. Additional female hearts underwent sarcKATP antagonism during I/R by HMR-1098 (HMR), either alone or in combination with Chel (HMR + Chel). GISC hearts were fractionated to assess cellular distribution of PKCe{open} and sarcKATP. Sex-specific infarct resistance was apparent under control I/R (F, 23 ± 3% vs. M, 36 ± 4%, P < 0.05) and abolished by Chel (F + C, 36 ± 3%). Female infarct resistance was susceptible to sarcKATP blockade (Control, 16 ± 2% vs. HMR, 27 ± 3%), and PKC blockade had no additional effect (HMR + Chel, 26 ± 2%). The prevalence of Kir6.2 and SUR2 was higher in the sarcolemmal fractions of females (Kir6.2: F, 1.24 ± 0.07 vs. M, 1.02 ± 0.06; SUR2: F, 3.16 ± 0.22 vs. M, 2.45 ± 0.09; ratio units), but normalized by Chel (Kir6.2: F, 1.06 ± 0.07 vs. M, 0.99 ± 0.06; SUR2: F, 2.99 ± 0.09 vs. M, 2.82 ± 0.22, M; ratio units). Phosphorylation of sarcolemmal PKCe{open} was reduced by Chel (p-PKCe{open}/PKCe{open}: control, 0.43 ± 0.02; Chel, 0.29 ± 0.01; P < 0.01). We conclude that PKC-mediated regulation of sarcKATP may account for the physiologically sustainable dependence of SSC upon both PKC and sarcKATP, and that this regulation involves PKC-permitted enrichment of the female sarcolemma with sarcKATP. As such, the PKC-sarcKATP axis may represent a target for sustainable prophylactic induction of cardioprotection.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5723-5737 |
| Number of pages | 15 |
| Journal | Journal of Physiology |
| Volume | 587 |
| Issue number | 23 |
| DOIs | |
| State | Published - Dec 1 2009 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Physiology
Cite this
PKC-permitted elevation of sarcolemmal KATP concentration may explain female-specific resistance to myocardial infarction. / Edwards, Andrew G.; Rees, Meredith L.; Gioscia, Rachel A.; Zachman, Derek K.; Lynch, Joshua M.; Browder, Jason C.; Chicco, Adam J.; Moore, Russell L.
In: Journal of Physiology, Vol. 587, No. 23, 01.12.2009, p. 5723-5737.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - PKC-permitted elevation of sarcolemmal KATP concentration may explain female-specific resistance to myocardial infarction
AU - Edwards, Andrew G.
AU - Rees, Meredith L.
AU - Gioscia, Rachel A.
AU - Zachman, Derek K.
AU - Lynch, Joshua M.
AU - Browder, Jason C.
AU - Chicco, Adam J.
AU - Moore, Russell L.
PY - 2009/12/1
Y1 - 2009/12/1
N2 - The female myocardium, relative to that of the male, exhibits sustained resistance to ischaemic tissue injury, a phenomenon termed sex-specific cardioprotection (SSC). SSC is dependent upon the sarcolemmal KATP channel (sarcKATP), and protein kinase C (PKC). Here we investigate whether PKC-mediated regulation of sarcKATP concentration can explain this endogenous form of protection. Hearts from male (M) and female (F) rats were Langendorff-perfused for 30 min prior to either regional ischaemia-reperfusion (I/R), or global ischaemia (GISC). For both protocols, pre-ischaemic blockade of PKC was achieved by chelerythrine (Chel) in male (M + C) and female (F + C) hearts. Additional female hearts underwent sarcKATP antagonism during I/R by HMR-1098 (HMR), either alone or in combination with Chel (HMR + Chel). GISC hearts were fractionated to assess cellular distribution of PKCe{open} and sarcKATP. Sex-specific infarct resistance was apparent under control I/R (F, 23 ± 3% vs. M, 36 ± 4%, P < 0.05) and abolished by Chel (F + C, 36 ± 3%). Female infarct resistance was susceptible to sarcKATP blockade (Control, 16 ± 2% vs. HMR, 27 ± 3%), and PKC blockade had no additional effect (HMR + Chel, 26 ± 2%). The prevalence of Kir6.2 and SUR2 was higher in the sarcolemmal fractions of females (Kir6.2: F, 1.24 ± 0.07 vs. M, 1.02 ± 0.06; SUR2: F, 3.16 ± 0.22 vs. M, 2.45 ± 0.09; ratio units), but normalized by Chel (Kir6.2: F, 1.06 ± 0.07 vs. M, 0.99 ± 0.06; SUR2: F, 2.99 ± 0.09 vs. M, 2.82 ± 0.22, M; ratio units). Phosphorylation of sarcolemmal PKCe{open} was reduced by Chel (p-PKCe{open}/PKCe{open}: control, 0.43 ± 0.02; Chel, 0.29 ± 0.01; P < 0.01). We conclude that PKC-mediated regulation of sarcKATP may account for the physiologically sustainable dependence of SSC upon both PKC and sarcKATP, and that this regulation involves PKC-permitted enrichment of the female sarcolemma with sarcKATP. As such, the PKC-sarcKATP axis may represent a target for sustainable prophylactic induction of cardioprotection.
AB - The female myocardium, relative to that of the male, exhibits sustained resistance to ischaemic tissue injury, a phenomenon termed sex-specific cardioprotection (SSC). SSC is dependent upon the sarcolemmal KATP channel (sarcKATP), and protein kinase C (PKC). Here we investigate whether PKC-mediated regulation of sarcKATP concentration can explain this endogenous form of protection. Hearts from male (M) and female (F) rats were Langendorff-perfused for 30 min prior to either regional ischaemia-reperfusion (I/R), or global ischaemia (GISC). For both protocols, pre-ischaemic blockade of PKC was achieved by chelerythrine (Chel) in male (M + C) and female (F + C) hearts. Additional female hearts underwent sarcKATP antagonism during I/R by HMR-1098 (HMR), either alone or in combination with Chel (HMR + Chel). GISC hearts were fractionated to assess cellular distribution of PKCe{open} and sarcKATP. Sex-specific infarct resistance was apparent under control I/R (F, 23 ± 3% vs. M, 36 ± 4%, P < 0.05) and abolished by Chel (F + C, 36 ± 3%). Female infarct resistance was susceptible to sarcKATP blockade (Control, 16 ± 2% vs. HMR, 27 ± 3%), and PKC blockade had no additional effect (HMR + Chel, 26 ± 2%). The prevalence of Kir6.2 and SUR2 was higher in the sarcolemmal fractions of females (Kir6.2: F, 1.24 ± 0.07 vs. M, 1.02 ± 0.06; SUR2: F, 3.16 ± 0.22 vs. M, 2.45 ± 0.09; ratio units), but normalized by Chel (Kir6.2: F, 1.06 ± 0.07 vs. M, 0.99 ± 0.06; SUR2: F, 2.99 ± 0.09 vs. M, 2.82 ± 0.22, M; ratio units). Phosphorylation of sarcolemmal PKCe{open} was reduced by Chel (p-PKCe{open}/PKCe{open}: control, 0.43 ± 0.02; Chel, 0.29 ± 0.01; P < 0.01). We conclude that PKC-mediated regulation of sarcKATP may account for the physiologically sustainable dependence of SSC upon both PKC and sarcKATP, and that this regulation involves PKC-permitted enrichment of the female sarcolemma with sarcKATP. As such, the PKC-sarcKATP axis may represent a target for sustainable prophylactic induction of cardioprotection.
UR - http://www.scopus.com/inward/record.url?scp=71249104769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71249104769&partnerID=8YFLogxK
U2 - 10.1113/jphysiol.2009.181040
DO - 10.1113/jphysiol.2009.181040
M3 - Article
C2 - 19805744
AN - SCOPUS:71249104769
VL - 587
SP - 5723
EP - 5737
JO - Journal of Physiology
JF - Journal of Physiology
SN - 0022-3751
IS - 23
ER -